CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
65.55
-1.27 (-1.90%)
At close: Apr 28, 2026, 4:00 PM EDT
65.55
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:54 PM EDT
CG Oncology Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for CG Oncology stock have an average target of 77.64, with a low estimate of 50 and a high estimate of 100. The average target predicts an increase of 18.44% from the current stock price of 65.55.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 5 | 5 |
| Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $73 → $79 | Buy | Maintains | $73 → $79 | +20.52% | Apr 27, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $65 → $91 | Buy | Maintains | $65 → $91 | +38.83% | Apr 17, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $100 | Strong Buy | Maintains | $80 → $100 | +52.56% | Apr 7, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $75 → $80 | Strong Buy | Maintains | $75 → $80 | +22.04% | Feb 27, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $66 → $75 | Strong Buy | Maintains | $66 → $75 | +14.42% | Feb 10, 2026 |
Financial Forecast
Revenue This Year
17.70M
from 4.04M
Increased by 338.00%
Revenue Next Year
135.98M
from 17.70M
Increased by 668.47%
EPS This Year
-2.57
from -2.08
EPS Next Year
-2.10
from -2.57
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 109.5M | 441.9M | ||||||
| Avg | 17.7M | 136.0M | ||||||
| Low | n/a | 24.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2,611.1% | 2,397.3% | ||||||
| Avg | 338.0% | 668.5% | ||||||
| Low | - | 38.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.64 | -0.24 | ||||||
| Avg | -2.57 | -2.10 | ||||||
| Low | -3.16 | -2.92 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.